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ABSTRACT
Objectives: The growing number of economic evaluations
that use data collected in multinational clinical trials raises
numerous questions regarding their execution and interpre-
tation. Although recommendations for conducting economic
evaluations have been widely disseminated, relatively little
guidance has been given for conducting economic evaluations
alongside clinical trials, particularly multinational trials.
Methods: Building on a literature review that was conducted
in preparation for an expert workshop, we evaluated a subset
of methodological issues related to conducting economic
evaluations alongside multinational clinical trials.
Results: We found wide variation in the types of costs
included as part of the analyses and in the methods used to
assign costs to hospitalization events. Furthermore, we found
that the extrapolation of costs and survival outcomes beyond
the trial period is an inconsistent practice and is often not
dependent on whether a survival beneﬁt was observed in the
trial or on the epidemiology or practice patterns in the coun-
try to which the ﬁndings are directed.
Conclusions: Although the limited sample size precluded a
quantitative analysis of trial characteristics and their associ-
ations with the methodologies employed, our ﬁndings high-
light the need for more guidance to analysts regarding the
execution of economic evaluations using data from multina-
tional clinical trials. As the research community grapples
with the complexities of methodological and logistical issues
involved in multinational economic evaluations, the develop-
ment of a standardized format to report the basic methodo-
logical characteristics of such studies would help to improve
transparency and comparability for other analysts and
decision-makers.
Keywords: cardiology, clinical trials, costs and cost analysis.
Introduction
Modern clinical trials must be designed to address sev-
eral converging trends, including the diminishing mag-
nitude of clinical beneﬁt expected beyond what can be
achieved with contemporary medical treatments, the
growing desire for outcome-oriented end points, and
expanding requirements for economic evaluations of
new therapies. One consequence of these trends has
been an increase in the number of patients enrolled in
individual clinical trials [1,2]. The challenge of recruit-
ing thousands of eligible patients in an expeditious
manner has increasingly been met by crossing interna-
tional borders. Also, to meet the needs of decision-
makers in regulatory, reimbursement, and managed
care settings, many clinical trials now incorporate eco-
nomic end points that require collection of resource
use data as part of the trial design. The joint effect of
these trends has been the proliferation of economic
evaluations conducted alongside multinational clinical
trials.
The growth in the number of economic evaluations
that use data from multinational clinical trials has
raised questions concerning how best to conduct and
interpret such analyses [3]. Although recommenda-
tions for conducting economic evaluations have been
widely disseminated [4,5], relatively little guidance has
been given for conducting economic evaluations along-
side clinical trials [6], and even less attention has been
given to issues speciﬁc to multinational trial settings.
Nevertheless, several recent reports have addressed the
difﬁcult issues of generalizability and cross-national
comparisons of costs in economic evaluations [3,7–
11]. The complexities of multinational economic eval-
uations are neither minor nor academic, because the
validity and generalizability of economic evaluations
are critically important to decision-makers around the
world who rely on cost-effectiveness information.
In a 2003 workshop on conducting economic eval-
uations alongside multinational clinical trials [9],
experts focused on developing a categorization scheme
for different approaches to conducting multinational
economic evaluations, including advantages and dis-
advantages of various approaches and a literature
review of economic evaluations conducted alongside
multinational clinical trials in cardiology. Although
this article draws on the literature review conducted in
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preparation for the workshop, our focus is different.
Here we explore additional issues raised at the meet-
ing—speciﬁcally, the types of costs included in the
analysis, the costing strategies employed, and the
extrapolation of costs and outcomes beyond the clin-
ical trial period.
Types of Costs, Costing Strategies, and Extrapolation of 
Costs and Outcomes Beyond the Trial
Guidelines for conducting economic evaluations rec-
ommend that the time horizon for the evaluation of
costs be consistent with the time horizon necessary to
capture all downstream, health-related effects of the
intervention [4,5]. This goal is usually accomplished
through reliance on primary data to represent short-
term effects and some type of modeling exercise to
extrapolate costs and health outcomes to a longer-term
time horizon. There is little debate that inclusion of
disease-related costs, including downstream costs, is
necessary in economic evaluations of medical inter-
ventions. Disagreement does exist, however, about
whether medical costs not associated with the condi-
tion under study should be considered [4,5,12]. Some
experts argue that both disease-related and unrelated
medical costs should be included in economic evalua-
tions, because it is often difﬁcult to differentiate
between costs that are associated with the disease and
those that are not [13]. An opposing view holds that
focusing only on disease-related costs allows greater
precision in detecting the effects of the treatment by
minimizing the “noise” that occurs when all costs are
included [12]. In addition, there is debate regarding the
inclusion of future costs for unrelated medical and
nonmedical costs incurred during added years of life
[5,14,15]. Reﬂecting this ongoing debate, the Panel on
Cost-Effectiveness in Health and Medicine suggests
excluding future unrelated costs from the reference-
case analysis but exploring the impact of their inclu-
sion in sensitivity analysis [4]. Lastly, the handling of
indirect costs is another source of debate [13].
Additional Considerations Related to Costing in 
Multinational Settings
In multinational settings, theoretical and methodolog-
ical issues regarding unit costs and cost assignment are
complex. First, unit costs for medical resources differ
across countries. Second, the availability of medical
resources differs across countries. Third, indirect costs
resulting from lost productivity and friction costs vary
because of wage rates and worker productivity. It is
also likely that the propensity for patients with the
same health status to drop out of the workforce differs
across countries with various social welfare systems
and sociocultural norms [16]. In addition, patient
demographics, the epidemiology of disease, and clini-
cal practice environments vary considerably across
international borders [7]. The intensity of medical
resource use for the same condition may similarly vary.
These variations can complicate multinational clinical
trials, because pooled resource use data may not apply
to individual locales or their decision-makers [11].
This problem is exacerbated by the variation in meth-
odological approaches in economic evaluations, par-
ticularly the extent to which analysts allow resource
use to vary by country [10].
Additional Considerations Related to Extrapolation of 
Within-Trial Outcomes in Multinational Settings
As noted above, international differences in patient
characteristics and clinical practice patterns exist.
Assuming that these factors are associated with long-
term survival and costs, methodological and interpre-
tative difﬁculties arise when within-trial outcomes are
extrapolated to a longer time horizon. For example,
should extrapolation of survival be based on some par-
ametric extrapolation of the data collected in the trial,
thus producing estimates that reﬂect the study popu-
lation? Or, for analysts attempting to customize the
analysis for a particular country, should the extrapo-
lation of survival be more speciﬁc? If sample size
allows, parametric extrapolation based on a selected
patient subgroup can be performed or epidemiological
data from the country of interest can be applied to the
trial population so that estimates might better reﬂect
life expectancy in that country. Similar issues arise for
extrapolation of costs beyond the trial period, because
costs and the intensity of medical resource use vary
across countries through different stages of disease.
How can these issues be handled adequately in a
multinational economic evaluation? Using the basic
framework of types of costs discussed above, this arti-
cle focuses on three of these issues. Speciﬁcally, we
sought to describe the types of costs that have been
considered in published studies and how they have
been estimated in economic evaluations conducted
alongside multinational clinical trials in cardiology.
We also sought to describe whether analysts extrapo-
lated cost and survival outcomes beyond the trial
period. In addition to the descriptive analysis, we also
attempted to identify trial characteristics that may
be associated with the methodological strategies
employed in the studies.
Methods
The economic evaluations included in this analysis were
identiﬁed in a previous literature review [9]. The liter-
ature search was conducted using MEDLINE and Inter-
national Pharmaceutical Abstracts to identify economic
evaluations conducted alongside multinational clinical
trials in cardiology. Additional studies were located
through contact with authors and by reviewing bibli-
ographies of clinical and economic reports from multi-
national clinical trials. Relevant articles were limited to
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those that used patient-level data as the basis for the
analysis. Articles in which an economic model served as
the primary analytic framework were excluded to main-
tain consistency among the analyses reviewed.
Results
Twenty-three studies met our inclusion criteria. The
studies ranged in size from 471 to 41,021 patients and
tested a variety of treatments, including angiotensin-
converting enzyme (ACE) inhibitors, tissue plasmino-
gen activator (tPA), and glycoprotein IIb/IIIa receptor
inhibitors. The studies generally enrolled patients from
Europe and North America, although some studies
also enrolled patients from South and Central Amer-
ica. Of the 23 studies, 5 were limited to within-trial
cost comparisons. The remaining 18 studies included
cost-effectiveness (or cost-utility) analyses and form
the basis of this analysis [17–34].
Table 1  provides a summary of the studies, includ-
ing the names of the clinical trials on which the eco-
nomic evaluations were based, the number of countries
represented in the trials, and the interventions under
study. Of the 18 studies, 3 were based on the Platelet
Glycoprotein IIb/IIIa in Unstable Angina: Receptor
Suppression Using Integrilin Therapy (PURSUIT) trial,
which compared eptiﬁbatide to placebo in patients with
acute coronary syndrome; 2 were based on the Heart
Outcomes Prevention Evaluation trial, which evaluated
the efﬁcacy of the ACE inhibitor ramipril relative to pla-
cebo in patients at high risk for cardiovascular events;
and 2 were based on the Studies of Left Ventricular
Dysfunction trial, which compared the ACE inhibitor
enalapril and placebo in patients with heart failure. The
other trials included in our analysis were represented
by only one economic evaluation each, thereby limiting
our ability to evaluate the impact of methodological
variations applied to the same trial data.
Table 1 Characteristics of the clinical trials
Report
Trial, 
sample size
Number of 
countries Comparison and patient population
Patients
hospitalized at
randomization
Costing begun
with index
hospitalization
Bjorholt et al. [17] HOPE,
n = 9297
19 Ramipril vs. placebo in patients at high risk of 
cardiovascular events
No No
Brown and
Armstrong [18]
PURSUIT,
n = 10,948
28 Eptiﬁbatide vs. placebo in patients with acute 
coronary syndrome
Yes Yes
Brown et al. [19] PURSUIT,
n = 10,948
28 Eptiﬁbatide vs. placebo in patients with acute 
coronary syndrome
Yes Yes
Cathomas et al. [20] PREVENT,
n = 825
2 Amlodipine vs. placebo in patients with coronary 
atherosclerosis
No No
Cook et al. [21] SOLVD,
n = 6797
3 Enalapril vs. placebo in patients with left ventricular 
dysfunction and hypertension
No No
Dasbach et al. [22] ELITE,
n = 722
3+ Losartan vs. captopril in patients with heart failure No No
Ekman et al. [23] CIBIS II,
n = 2647
18 Bisoprolol vs. placebo in patients with heart failure No No
Erhardt et al. [24] AIRE,
n = 1986
14 Ramipril vs. placebo in patients with heart failure after 
acute myocardial infarction
Most* Not reported
Glick et al., 1995 [25] SOLVD,
n = 2569
3 Enalapril vs. placebo in patients with heart failure No No
Glick et al., 2002 [26] RALES,
n = 1663
16 Spironolactone vs. placebo in patients with severe 
heart failure
No No
Jonsson et al. [27] 4S,
n = 4444
5 Simvastatin vs. placebo in patients with angina or 
prior myocardial infarction
No No
Lamy et al. [28] HOPE,
n = 9297
19 Ramipril vs. placebo in patients at high risk for 
cardiovascular events
No No
Mark et al., 2000 [29] PURSUIT,
n = 10,948
28 Eptiﬁbatide vs. placebo in patients with acute 
coronary syndrome
Yes Yes
Mark et al., 1995 [30] GUSTO,
n = 41,021
15 Tissue plasminogen activator vs. streptokinase for 
acute myocardial infarction
Yes Yes
Reed et al. [31] Val-HeFT,
n = 5010
18 Valsartan vs. placebo in patients with heart failure No No
Schulman et al. [32] FIRST,
n = 471
14 Epoprostenol vs. placebo in patients with severe 
heart failure
Yes Yes
Sculpher et al. [33] ATLAS,
n = 3164
19 Low-dose vs. high-dose lisinopril in patients with 
heart failure
No No
Topol et al. [34] EPISTENT,
n = 2399
2 Abciximab plus angioplasty vs. stenting plus abciximab 
vs. stenting plus placebo in patients undergoing 
percutaneous coronary revascularization
Yes Yes
*We assumed that most patients would have been hospitalized at the time of randomization, which occurred 3–10 days after an acute myocardial infarction.
AIRE, Acute Infarction Ramipril Efﬁcacy study; ATLAS, Assessment of Treatment with Lisinopril and Survival study; CIBIS II, Cardiac Insufﬁciency Bisoprolol Study II; ELITE, Eval-
uation of Losartan in the Elderly; EPISTENT, Evaluation of Platelet IIb/IIIa Inhibitor for Stenting; FIRST, Flolan International Randomized Survival Trial; 4S, Scandinavian Simvastatin
Survival Study; GUSTO, Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries; HOPE, Heart Outcomes Prevention
Evaluation study; PREVENT, Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial; PURSUIT, Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor
Suppression Using Integrilin Therapy; RALES, Randomized Aldactone Evaluation Study; SOLVD, Studies of Left Ventricular Dysfunction; Val-HeFT, Valsartan Heart Failure Trial.
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Types of Costs Considered During the Trial and Methods 
Used to Estimate Costs
In our sample of studies from the cardiology literature,
the main focus of within-trial estimation of costs was
on hospital care and study medications. Twelve studies
focused their primary analyses on total medical costs
(disease-related and unrelated medical costs); the
remaining six studies were limited to medical costs
related to cardiovascular disease (Table 2).
Four general approaches were used to assign direct
medical costs for each hospitalization (Table 2). Ana-
lysts either 1) assigned a ﬁxed cost to each hospitali-
zation according to the reason for hospitalization; 2)
assigned unit costs to individual resources used during
the hospitalization; 3) assigned costs based on length
of stay; or 4) relied on hospital billing data.
Four studies applied a combination of costing meth-
ods [23,29,30,34]. Approximately one-third of the
studies applied a “ﬁxed” costing method, akin to diag-
nosis-related group (DRG) costs that, while indirectly
incorporating the time patients spent in the hospital by
using mean costs for speciﬁc diagnoses, did not adjust
costs based on the duration of hospitalization or inten-
sity of care experienced by individual patients
[17,20,21,23,25,27,28,30]. Most of the studies esti-
mated costs using methods that captured differences in
length of hospitalization between patients [18,22–
24,26,29–34]. Among these studies, four applied
generic per diem unit costs to days in the hospital or
days in various hospital wards, but did not vary costs
according to the reason for admission [22–24,32].
Three studies combined the reason for admission with
data on length of stay, thereby better approximating
the variation in costs that occurs between patients
[26,31,33]. Analysts relied on hospital bills to estimate
inpatient costs in only two studies [29,34]. Bottom-up
methods that rely on individual counts of resource use
to estimate inpatient costs were applied in four studies
[18,29,30,34].
In only a few cases did analysts explicitly present a
rationale for their cost-estimation methods. In the
study by Bjorholt et al. [17], which applied ﬁxed costs
to hospitalizations classiﬁed using DRGs, the authors
stated that group differences were expected to be
observed in the incidence of hospitalization, not in the
management of patients after they were hospitalized.
Topol et al. [34] used hospital bills and reported that
they had decided during the trial’s design phase to
Table 2 Methods for cost determination and reporting in multinational cardiovascular clinical trials
Report
Trial, 
sample size
Source of cost data, 
country used for 
estimation, and sample 
size for estimation*
Total vs. 
cardiovascular 
hospital costs
Method of cost 
estimation Details of cost estimation
Bjorholt et al. [17] HOPE,
n = 9297
Swedish costs applied to 
Swedish patients 
(n = 537)
Primary: 
cardiovascular 
Secondary†: 
total
Fixed‡ DRG-based costs assigned to 
cardiovascular hospitalizations 
for admission plus 
noncardiovascular 
admissions (in tertiary 
analyses)
Brown and
Armstrong [18]
PURSUIT,
n = 10,948
Canadian costs applied to 
Canadian patients 
(n = 305)
Total Adjusted for resource 
use
Per diem for CCU and general 
ward, diagnostic and 
therapeutic procedures, 
transfusions, and medications
Brown et al. [19] PURSUIT,
n = 10,948
Costs from 6 countries in 
Western Europe 
applied separately to all 
patients from 15 
countries in Western 
Europe (n = 3697)
Total Other Mean rates of resource use 
observed in trial (e.g., hospital 
days, diagnostic tests) 
multiplied by unit costs to 
obtain mean cost per patient in 
each arm
Cathomas et al. [20] PREVENT,
n = 825
Swiss costs applied to all 
patients (n = 825)
Cardiovascular Fixed‡ Costs only assigned to 
hospitalizations for acute MI, 
stroke, CABG, and PCI
Cook et al. [21] SOLVD,
n = 6797
US costs applied to all 
patients with 
hypertension 
(n = 1917)
Total Fixed‡ DRG-based costs assigned to 
hospitalizations for 9 
cardiovascular reasons for 
admission plus 
noncardiovascular admissions
Dasbach et al. [22] ELITE,
n = 722
US costs applied to all 
patients (n = 722)
Total Adjusted for length of 
stay§
Number of hospital days 
multiplied by average-per-day 
US Medicare payment
Ekman et al. [23] CIBIS II,
n = 2647
Swedish costs applied to 
all patients (n = 2647)
Total Fixed‡ and adjusted for 
length of stay§
DRG-based costs assigned to 
hospitalizations for 13 
cardiovascular reasons for 
admission plus 
noncardiovascular admissions; 
cost per day in cardiology 
ward, ICU, general ward, and 
other ward by length of stay 
per ward
(continued)
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Erhardt et al. [24] AIRE,
n = 1986
Swedish costs applied to 
Swedish patients 
(n = 162)
Primary: 
cardiovascular 
Secondary†: 
total
Adjusted for length of 
stay§
Data on length of stay and ward 
retrospectively collected from 
4 Swedish clinics participating 
in trial and combined with unit 
cost data from 1 county 
hospital
Glick et al., 1995 [25] SOLVD,
n = 2569
US costs applied to all 
patients (n = 2569)
Total Fixed‡ DRG-based costs assigned to 
hospitalizations for 9 
cardiovascular reasons for 
admission plus noncardiovascu-
lar admissions
Glick et al., 2002 [26] RALES,
n = 1663
Country-speciﬁc costs 
applied to all patients 
(n = 1663)
Total Adjusted for length of 
stay||
Multiplied days in the hospital (by 
reason for admission) by 
admission-speciﬁc daily cost 
estimates for individual 
countries
Jonsson et al. [27] 4S,
n = 4444
Swedish costs applied to 
all patients (n = 4444)
Cardiovascular Fixed‡ DRG-based costs assigned to 
hospitalizations for 25 
cardiovascular events
Lamy et al. [28] HOPE,
n = 9297
US and Canadian costs 
applied separately to all 
patients (n = 9297)
Cardiovascular Fixed‡ DRG-based costs assigned to 
hospitalizations for 11 
cardiovascular events
Mark et al., 2000 [29] PURSUIT,
n = 10,948
US costs applied to US 
patients (n = 3522)
Total Hospital bills and 
adjusted for 
resource use
Hospital bills collected for 70% 
random sample of US patients; 
linear regression models used 
to assign costs to patients 
without bills
Mark et al., 1995 [30] GUSTO,
n = 41,021
US costs applied to US 
patients (n = 23,105)
Cardiovascular Index hospitalizations 
adjusted for 
resource
use; rehospitaliza-
tions ﬁxed‡
Unit costs from 1 hospital cost 
accounting system applied to 
inpatient resources consumed 
for initial hospitalization; DRG-
based costs assigned for 11 
cardiovascular events for 
rehospitalizations
Reed et al. [31] Val-HeFT,
n = 5010
Country-speciﬁc costs 
applied to all patients 
(n = 5010)
Total Adjusted for length of 
stay||
Multiplied days in hospital (by 
reason for admission) by 
admission-speciﬁc daily cost 
estimates for individual 
countries
Schulman et al. [32] FIRST,
n = 471
US costs applied to all 
patients (n = 471)
Total Adjusted for length of 
stay§
Per diem costs for days in general 
ward, CCU, and ICU derived 
from 1 hospital cost accounting 
system and applied to length of 
stay for each ward
Sculpher et al. [33] ATLAS,
n = 3164
UK costs applied to all 
patients (n = 3164)
Total Adjusted for length of 
stay||¶
Per diem costs for hospital days 
estimated for individual 
medical specialties assigned to 
hospital days based on reason 
for admission
Topol et al. [34] EPISTENT,
n = 2399
US costs applied to US 
patients (n = 1438)
Total Index hospitalizations 
based on hospital 
bills; rehospitaliza-
tions adjusted for 
resource use
Hospital bills used to estimate 
costs for initial hospitalization; 
costs for rehospitalizations 
estimated with linear regres-
sion model based on empirical 
follow-up cost data from 
another trial
Report
Trial, 
sample size
Source of cost data, 
country used for 
estimation, and sample 
size for estimation*
Total vs. 
cardiovascular 
hospital costs
Method of cost 
estimation Details of cost estimation
Table 2 continued
*Adapted from Reed et al. [9].
†Refers to sensitivity analyses or secondary/tertiary analyses.
‡Applied a “ﬁxed” costing method, akin to DRG costs that, while indirectly incorporating the time patients spent in the hospital by using mean costs for
speciﬁc diagnoses, did not adjust costs based on the duration of hospitalization or intensity of care experienced by individual patients.
§Applied generic per diem unit costs to days in the hospital or days in various hospital wards, but did not vary costs according to the reason for admission.
||Combined the reason for admission with data on length of stay to approximate the variation in costs that occurs between patients.
¶Because the analysis used reason for hospitalization to determine which medical specialty per diem estimate would be assigned, we categorized the
costing methods with others that used both reason for admission and data on length of stay.
AIRE, Acute Infarction Ramipril Efﬁcacy study; ATLAS, Assessment of Treatment with Lisinopril and Survival study; CABG, coronary artery bypass graft
surgery; CCU, cardiac care unit; CIBIS II, Cardiac Insufﬁciency Bisoprolol Study II; DRG, diagnosis-related group; ELITE, Evaluation of Losartan in the
Elderly; EPISTENT, Evaluation of Platelet IIb/IIIa Inhibitor for Stenting; FIRST, Flolan International Randomized Survival Trial; 4S, Scandinavian Simvastatin
Survival Study; GUSTO, Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries study; HOPE, Heart
Outcomes Prevention Evaluation study; MI, myocardial infarction; PCI, percutaneous coronary intervention; PREVENT, Prospective Randomized Evalu-
ation of the Vascular Effects of Norvasc Trial; PURSUIT, Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy;
RALES, Randomized Aldactone Evaluation Study; SOLVD, Studies of Left Ventricular Dysfunction; Val-HeFT, Valsartan Heart Failure Trial.
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collect hospital bills only for the index hospitalization
as a means to “obtain an accurate estimate of any
potential offset” from the study drug. Nevertheless, it
appeared that characteristics of the trial were associ-
ated with cost assignment. All of the studies that used
hospital bills [29,34] or bottom-up costing methods
[18,29,30,34] were included among the trials that
randomized patients when they were hospitalized
[17,18,29,30,32,34].
The design of the clinical trial was also the main
determinant as to whether inpatient costs were inclu-
sive of the index hospitalization. Economic evaluations
of the six clinical trials that randomized patients while
they were hospitalized for an acute condition (e.g.,
severe heart failure, acute myocardial infarction) or
surgical procedure (e.g., percutaneous coronary inter-
vention) included the cost of the index hospitalization
[17,18,29,30,32,34].
With regard to sources of unit cost data and assign-
ment of these costs to patients from various countries,
the most common approach—applied in nine studies—
was to assign a set of unit costs from one country to
resource use by all patients enrolled in the trial
(Table 2) [20–23,25,27,28,32,33]. In six studies, cost
estimation was limited to patients from one country
[17,18,24,25,29,30,34]. For additional details about
the unit costs and representation of countries for esti-
mates of costs and health outcomes, see Reed et al.
[31].
Extrapolation of Costs and Outcomes Beyond 
the Trial Period
Of the 18 cost-effectiveness evaluations reviewed, 12
were based on trials that demonstrated a signiﬁcant
difference in within-trial, all-cause mortality (Table 3).
In 3 of these 12 trials, analysts did not extrapolate
costs or survival beyond the duration of the trial
[24,26,28]. Lamy et al. [28] reported cost-effectiveness
ratios as the incremental cost per end point saved.
Erhardt et al. [24] and Glick et al. [26] based the
denominators of the incremental cost-effectiveness
ratios on differences in within-trial survival, thereby
generating conservative estimates of cost-effectiveness.
The remaining 9 of 12 studies demonstrated signiﬁcant
reductions in within-trial, all-cause mortality and
extrapolated survival to a lifetime perspective using a
variety of methods (Table 4).
Four studies did not demonstrate a signiﬁcant dif-
ference in mortality but did estimate lifetime survival
(Table 2). Three of the four were based on PURSUIT,
a trial of eptiﬁbatide for acute coronary syndromes.
The trial showed a signiﬁcant reduction in the primary
end point—death or acute myocardial infarction at
30 days—but not in overall mortality. In the subse-
quent economic evaluations, estimation of survival
after 6 months was based on Cox proportional haz-
ards models that used long-term survival data from an
observational data set of postmyocardial infarction
patients from one medical center in the United States
[18,19,29]. Survival estimation for the United States
and Canadian economic evaluations was based on
characteristics of trial patients from North America,
whereas the European adaptation was based on char-
acteristics of patients from Western Europe. Because
this trial demonstrated a reduction in the primary end
point among US patients but not among Western Euro-
pean patients, these studies are important in that they
demonstrate the potential for variations in the results
of multinational clinical trials that can have important
effects on the results of economic evaluations. The
other economic evaluation that extrapolated survival
estimates despite a nonsigniﬁcant reduction in all-
cause mortality was based on the Prospective Rand-
omized Evaluation of the Vascular Effects of Norvasc
Trial (PREVENT), which showed no reductions in
mortality, progression to atherosclerosis, or risk of
major cardiovascular events, but was associated with a
reduction in hospitalizations for unstable angina and
coronary revascularization procedures [20].
Although it is not necessary that a clinical trial dem-
onstrate a statistically signiﬁcant mortality beneﬁt to
extrapolate life expectancy beyond the trial period,
assessment and reporting of uncertainty associated
with the study’s results is warranted. For example, in
the economic evaluation of the PREVENT trial,
although sensitivity analyses were conducted to vary
the point estimate of a 0.083 gain in life expectancy by
±20%, these analyses were insufﬁcient to represent the
underlying uncertainty associated with the nonsigniﬁ-
cant mortality effect observed in the clinical trial. In
fact, fewer than half of the studies we evaluated
included information on the stochastic uncertainty
associated with the studies’ cost-effectiveness ﬁndings
(e.g., conﬁdence intervals for cost-effectiveness ratios,
cost-acceptability curves) (Table 4). We did not
observe a temporal trend indicating that more recently
reported studies were more likely to have included
information on uncertainty; about half of the studies
(43%) that reported measures of uncertainty predated
2000, similar to the proportion of studies that did not
report measures of uncertainty (45%).
Table 3 Within-trial mortality ﬁndings and survival projection
in economic evaluations
Survival extrapolated beyond trial period
Signiﬁcant difference in 
all-cause mortality
Yes No Total
Yes 9 4* 13
No 3 2 5
Total 12 6 18
*In the three studies based on data from PURSUIT, there was a signiﬁcant reduction
in the incidence of death or acute myocardial infarction in the US subset at 30 days
(P = 0.002) but not in the Western European subset (P = 0.39).
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In 13 of the 18 studies reviewed, analysts did not
extrapolate the cost of study treatment beyond the trial
period in the primary analyses (Table 4). Nevertheless,
in ﬁve of these studies, this approach was appropriate
because the interventions under study (i.e., tPA and
eptiﬁbatide) were administered only once in an acute
care setting. In an additional ﬁve studies, the focus of
the analyses was on within-trial beneﬁts, and the time
frames for the evaluations of costs and clinical out-
comes were consistent. In the primary analyses of the
remaining three studies, the time frames were not con-
sistent [17,20,27]. In these studies, the long-term effect
of chronic medication use on survival was estimated,
but costs for treatment were not extrapolated over the
same time period (although Bjorholt et al. [17] did
project costs in a sensitivity analysis).
In four studies, both treatment and nontreatment
costs were projected over a lifetime perspective in the
primary analyses [21–23,25]. The cost projections
made in all four of these studies relied on the extrap-
olation of within-trial resource use or costs. These four
studies also projected survival and were thus consistent
in projecting total medical costs and survival [21–
23,25].
Two studies included future costs due to medical
and nonmedical consumption net of production in
years of extended survival due to treatment. One study
presented the data in the form of a sensitivity analysis
[17], and the other study included the calculations in
both primary and sensitivity analyses [23]. In both
cases, the inclusion of these costs markedly affected the
computed cost-effectiveness ratios. In the analysis by
Bjorholt et al. [17], the cost per life-year gained was
16,600 Swedish kroner (SEK) in the primary analysis.
When future costs were included, that ﬁgure rose to
208,300 SEK. In the study by Eckman et al. [23], the
Table 4 Time frame and projection of costs and survival
Report
Within-trial 
time frame
Economic
analysis 
time frame
Treatment
costs 
projected*
Other 
medical
costs 
projected†
Future 
unrelated
costs 
included‡
Data source/
method for 
survival projection
Treatment
beneﬁt 
beyond 
trial period
Stochastic
uncertainty
for cost- 
effectiveness
results
Bjorholt et al. [17] 4.5 year Lifetime Secondary 
analysis§
Secondary 
analysis§
Secondary
analysis§
Actuarial data from 
Sweden
No No
Brown and 6 month Lifetime No|| No No DCDD No No
Armstrong [18]
Brown et al. [19] 6 month Lifetime No|| No No DCDD No No
Cathomas et al. [20] 3 year Lifetime No No No Actuarial data from 
Switzerland
Yes No
Cook et al. [21] 2.8 year Lifetime Yes Yes No Parametric Weibull failure 
time survival models 
for each treatment 
group
Yes Yes
Dasbach et al. [22] 48 week Lifetime Yes Yes No Actuarial data from the 
United States
No Yes
Ekman et al. [23] 1.3 year Lifetime Yes Yes Yes¶ Linear extrapolation 
assuming patients 
would live average of 5 
additional years
No No
Erhardt et al. [24] 3.8 year Within trial No No No None No No
Glick et al., 1995 [25] 4 year Lifetime Yes Yes No Parametric Weibull failure 
time survival models 
for each treatment 
group
Yes No
Glick et al., 2002 [26] 35 month Within trial No No No None No Yes
Jonsson et al. [27] 5.5 year Lifetime No No No Actuarial data from 
Sweden
No No
Lamy et al. [28] 4.5 year Within trial No No No None No Yes
Mark et al., 2000 [29] 6 month Lifetime No|| No No DCDD No No
Mark et al., 1995 [30] 1 year Lifetime No|| Secondary 
analysis§
No DCDD and parametric 
Gompertz survival 
function
No No
Reed et al. [31] 23 month Within trial No No No None No Yes
Schulman et al. [32] 5 month 1 year Yes Yes No Survival analysis to predict 
1-year survival
No Yes
Sculpher et al. [33] 4 year Within trial No No No None No Yes
Topol et al. [34] 1 year Lifetime No|| No No DCDD No No
*Refers to the intervention under evaluation in the analysis.
†Refers to other disease-related and/or unrelated medical costs.
‡Refers to the explicit inclusion of future costs due to medical and nonmedical consumption (costs) net of production in years of extended survival.
§Refers to sensitivity analyses or secondary/tertiary analyses.
||Treatment costs were not extrapolated, but the intervention under study represented a one-time, acute treatment.
¶Base case results reported with and without future costs.
DCDD, Duke Cardiovascular Disease Database.
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cost per life-year gained was 13,094 SEK exclusive of
future costs and 168,858 SEK when future net con-
sumption was considered.
Discussion
In this article, we have focused on a subset of issues
involved in the economic analysis of multinational
clinical trials—the types of costs considered, the cost-
ing methods employed, and whether analysts extrapo-
lated within-trial costs and outcomes beyond the
follow-up period in major multinational cardiovascu-
lar trials. We found that the studies reviewed were
remarkable both for similarities in their general
approaches and for subtle but important variations in
the details of their methods.
Overwhelmingly, the studies we examined focused
on assessment of direct medical costs. Moreover, most
of the studies were based on total medical costs (i.e.,
not costs limited to cardiovascular disease), but few
studies incorporated nonmedical or indirect costs.
Although these studies reﬂect the state of the art in
clinical trial-based economics research, they may also
be indicative of inconsistency among decision-makers
with regard to the importance of indirect costs, as well
as the compromises required to carry out economic
evaluations alongside large, multinational trials. Data
collection in these trials is expensive, requiring
resources for case report form design, data collection,
data monitoring, and data entry. Therefore, in condi-
tions for which cost drivers are well understood, such
as cardiovascular disease, truncated data collection
limited to the direct medical costs that are expected to
dominate total and incremental costs may be a reason-
able compromise. To the extent that there is a desire
for a broader perspective in assessing costs of new
medical therapies, the incremental costs and beneﬁts of
collecting these additional data should be weighed
against their exclusion from the analysis or their inclu-
sion through some type of modeling effort that relies
on secondary data.
Although all of the studies included hospital costs,
there was variation in the costing methods employed.
Some analysts assigned the same costs regardless of the
patient’s hospital experience (e.g., length of stay, com-
plications), whereas others attempted to account for
between-patient variation. It appears that the selection
of costing method was associated primarily with the
characteristics of the resource use data available from
the clinical trial. In some studies, only information
regarding the number of hospitalizations related to
cardiovascular disease was available to analysts (e.g.,
Jonsson et al. [27]), thereby restricting the analysts to
the “ﬁxed” costing method. In other analyses, data on
the number of cardiovascular-related hospitalizations
from the trial were supplemented with per diem cost
estimates and data on length of stay collected retro-
spectively from local centers that participated in the
trial to calculate total hospital costs (e.g., Erhardt et al.
[24]). Even in multinational trials from which more
detailed information, such as length of stay and reason
for admission, is available for all hospitalizations, ana-
lysts may be justiﬁed in the application of “ﬁxed” cost-
ing methods that do not account for variation in length
of stay between patients. Although this approach
reduces variance, which may not be desirable from a
statistical perspective, variations in length of stay in a
multinational setting may be more closely related to
variations in practice patterns between countries than
to variations in disease severity between patients. One
approach to address both issues is to apply country-
speciﬁc unit costs to hospital days experienced by
patients from those countries (e.g., see Reed et al. [31]
and Glick et al. [26]).
As noted previously, the application of one coun-
try’s unit costs to resources consumed by all patients in
the trial is a frequently applied method [9]. Neverthe-
less, this approach may be problematic for at least two
reasons. First, numerous studies demonstrate that
patterns of resource use vary across countries [35–38].
Second, assignment of one country’s unit costs to
resource use across patients in many countries runs
counter to the theoretical relationship between relative
prices and the use of substitutable resources that exists
across countries [39]. Nevertheless, there are many
practical reasons why analysts would choose to over-
look these considerations. One of the most important
reasons may be the accessibility of cost data from dif-
ferent countries. A related issue is the variation in
methods used to derive unit costs in individual coun-
tries [40]. Because many countries ﬁnance health care
through a centralized system, patient-level cost
accounting data may be nonexistent, and cost esti-
mates may include tariffs or other markups that do not
reﬂect opportunity costs. Another reason that analysts
assign country-speciﬁc costs may be that they consider
them to be most applicable and transparent to their
target audience. Two studies have shown that the cost
assignment methodology has very little impact on
qualitative ﬁndings from cost-effectiveness analyses
across countries with similar levels of economic devel-
opment [10,41]. Variations in results across countries
are more likely to be evident when analysts allow for
patient characteristics and resource use patterns to
vary between countries [10,41].
Although the inclusion of disease-related medical
costs as the basis for cost-effectiveness analysis has
been supported by consensus recommendations [12], it
has also been suggested that a more accurate evalua-
tion of costs would include costs for comorbidities,
loss of productivity, and consumption of nonmedical
resources brought about by improved survival due to
therapy [42]. Whether to project unrelated costs is an
area of ongoing research and debate and has impor-
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tant implications for the results of such studies.
Although the number of studies included in our review
is limited, it is notable that the only two studies that
included future medical and nonmedical costs were
conducted by analysts in Sweden [17,23], possibly
reﬂecting the extensive social welfare system that exists
in that country. When future costs were included, both
studies yielded cost-effectiveness ratios that were
approximately 12 times greater than ratios excluding
such costs. As noted by Ekman et al. [23], when these
costs are included, they “clearly dominate” other
costs. This conclusion is supported by assertions in the
literature that the inclusion of both disease-related and
unrelated future costs can signiﬁcantly alter the cost-
effectiveness ratio in economic evaluations [42,43].
With regard to extrapolation of within-trial out-
comes beyond the trial period, in trials where a signif-
icant survival beneﬁt was shown, most of the analyses
were based on projected estimates of costs and sur-
vival. Nevertheless, some analysts extrapolated out-
comes to a lifetime perspective when a survival beneﬁt
was not observed in the trial, and others chose not to
extrapolate even when a signiﬁcant mortality beneﬁt
was observed. A commonly used method of extrapo-
lating within-trial mortality to long-term survival esti-
mates was to apply the same mortality rate to patients
in both arms. This approach is often interpreted incor-
rectly to be as conservative as limiting ﬁndings to those
observed within the trial period, but accumulation of
beneﬁt occurs over time to a greater extent in the treat-
ment arm with improved survival at the end of the
study period [44].
It is interesting to note that, although the majority
of the articles reviewed provided substantial detail
regarding the methods they used for survival projec-
tions, few discussed the rationale behind the choice of
methodology. Thus, any interpretation of the authors’
choices of analytic methods would be speculative.
Nevertheless, we noted that in approximately half of
the studies, the analysts appeared to apply methods
to customize the analysis for an individual country
through the use of actuarial data from the target coun-
try [17,20,22,27] or through the use of survival data
representing a relevant patient cohort from the target
country [29,30,34]. In other studies, an intermediate
method was applied whereby patient characteristics
from the target country were used to customize sur-
vival projections that originally were based on mortal-
ity data from another country [18,19]. In the
remaining analyses, analysts used information from
the trial itself to extrapolate beyond the follow-up
period (e.g., parametric survival extrapolation), thus
representing the experience of the multinational mix-
ture of patients enrolled in the study.
Although we found that the methods employed in
the economic evaluations were generally consistent
with expert recommendations, we also noticed a great
deal of variation in the methodological details. These
subtle differences in methodology, which may go
unnoticed by many potential users of cost-effectiveness
analyses, could have important effects on the studies’
ﬁndings and could ultimately affect decision-making.
Another issue of concern was the amount of time that
was necessary to identify and decipher the methods
that had been employed. Even for decision-makers
with sufﬁcient training to appreciate the potential
implications of various analytic strategies, the time
required to compare methods and ﬁndings of eco-
nomic evaluations is substantial. It is likely that many
decision-makers would abandon such an undertaking,
thus undermining the potential impact of cost-
effectiveness analyses in the selection of the most efﬁ-
cient medical technologies.
Because the ﬁeld of economic evaluation alongside
multinational clinical trials continues to mature, a rea-
sonable interim step toward uniform standards by
which the majority of trial-based multinational eco-
nomic analyses could be conducted would be to con-
tinue development of both new methodologies to
evaluate variability in study results across countries
and consistent reporting frameworks for such analyses
and their results. The International Society for Phar-
macoeconomics and Outcomes Research Task Force
on Good Research Practices: Randomized Clinical Tri-
als—Cost-Effectiveness Analysis (RCT-CEA) has rec-
ommended three analytical approaches that could be
used to address between-country variation in eco-
nomic evaluations [6]. These include testing for homo-
geneity of study results across countries [45], use of
multivariate regression models to adjust for country-
level effects [41], and use of multilevel modeling [46].
In addition, Drummond et al. [11] recently published
recommendations for reporting the results of trial-
based economic evaluations for the purpose of increas-
ing their generalizability, or at least the ability to assess
their generalizability. Recommendations that speciﬁ-
cally address issues that arise in the multinational con-
text include the reporting of important features of the
different health-care systems in countries in the trial
and the reporting of variability in the study’s results by
location using quantitative analysis, such as multilevel
modeling, or sensitivity analysis.
We also recommend adoption of standard termi-
nology that can be used to classify multinational
economic evaluations based on which countries are
the sources of clinical effectiveness data, which are the
sources of resource use data, and which are the
sources of unit costs [9]. Standard terminology may
also reduce problems caused by space restrictions in
scientiﬁc journals that often necessitate truncation of
methods sections. We also agree with other commen-
tators that another step forward would be the publi-
cation of selected primary data (such as country-level
or patient-level data) and detailed methods on the
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Internet to allow for more thorough, critical evalua-
tion of economic studies performed alongside multina-
tional trials and to allow individual analysts to apply
local cost data to resource use data collected in such
trials.
Questions about which costs to consider in a mul-
tinational economic analysis, which costing methods
to use, and how to extrapolate within-trial outcomes
remain matters of ongoing debate. In many cases, these
decisions are dictated by practicality—that is, analysts
must rely on the data that are collected in the clinical
trial and, in many cases, the requests of decision-mak-
ers and journal reviewers trump theoretical and meth-
odological considerations. Nevertheless, we should
recognize that the globalization of clinical trials is
likely to continue, as is the increasing reliance on
health technology assessment for coverage decisions.
Thus, continued dialogue among methodologists and
decision-makers about the issues discussed in this arti-
cle is essential to move the ﬁeld forward.
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